登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06194734,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
入选标准第 2 条
Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least second-line systemic therapy;
入选标准第 3 条
Involved in other clinical trials within 4 weeks before enrollment;Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;
排除标准第 7 条
Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;
排除标准第 8 条
Eastern Cooperative Oncology Group performance status score of 0 or 1;
入选标准第 5 条
At least one measurable tumor lesion according to RECIST 1.1;
入选标准第 4 条
Other kinds of malignancies within 5 years;
排除标准第 2 条
Known history of human immunodeficiency virus (HIV) infection or current active hepatitis B or C infection;
排除标准第 11 条
Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before randomization;
入选标准第 9 条
Pregnant or lactating women;
排除标准第 12 条
Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06194734,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Males or females aged 18 to 75 years; Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma; Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least second-line systemic therapy; At least one measurable tumor lesion according to RECIST 1.1; Eastern Cooperative Oncology Group performance status score of 0 or 1; Life expectancy > 12 weeks; BMI≥16.0 and weight≥40 kg ; Adequate bone marrow, renal, and hepatic function; Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before randomization; Patients should participate in the study voluntarily and sign informed consent.排除标准:Exclusion Criteria:
Any patient who is known to have untreated central nervous system (CNS) metastasis; Other kinds of malignancies within 5 years; Gastrointestinal abnormalities; Cardiovascular and cerebrovascular diseases; Prior therapies with vascular targeting inhibitor; Previously treated with Irinotecan, Docetaxel and Tegafur Gimeracil Oteracil Potassium; Involved in other clinical trials within 4 weeks before enrollment;Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment; Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1; Uncontrolled massive ascites, pleural or pericardial effusion; Severe infection within 4 weeks prior to randomization (CTCAE > Grade 2); Known history of human immunodeficiency virus (HIV) infection or current active hepatitis B or C infection; Pregnant or lactating women; Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study. Other patients are not eligible for enrollment assessed by investigators.
引自 ClinicalTrials.gov, NCT06194734, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06194734,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。